Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Wellbeing Digital Sciences Inc KONEF

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company. The Company is focused on the development and implementation of clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. It operates through three segments: Wellbeing & IRP; KGK Science and Mindscape. It operates medical clinics across North America to help its patients access plant-based medicines, psychedelics, and other forms of mental health care, all of which have the potential to heal them of their physical and/or emotional pain. Its subsidiaries include Mindscape Ketamine & Infusions Therapy LLC, KGK Science Inc. and Integrated Rehab and Performance Ltd. It is supported by a network of North American clinics that provide therapies and other types of treatment to patients, as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.


GREY:KONEF - Post by User

Post by XeniaTechieon Oct 14, 2021 2:41pm
138 Views
Post# 34006325

2 significant clinical trials for $MEDI now underway!

2 significant clinical trials for $MEDI now underway!KetamineOne $MEDI.n announces single arm, open-label study of PTSD patients in PT programs at $MEDI IRP health clinics & pilot study in patients receiving IV ketamine infusion therapies treating depression. Solid news driving wider applications for $KONEF therapies! https://bit.ly/3oZCeHC
<< Previous
Bullboard Posts
Next >>